



June 19, 2015

## Dicerna to Present at the JMP Securities Life Sciences Conference 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Dicerna Pharmaceuticals, Inc.](#) (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the JMP Securities Life Sciences Conference. The presentation will take place at The St. Regis New York on Tuesday, June 23, 2015 at 4:30 p.m. ET in New York City.

A live webcast of the presentation can be accessed by visiting "[Events & Presentations](#)" in the Investors and Media section on the Company's website at [www.dicerna.com](http://www.dicerna.com). An archived replay of the webcast will be available on the Company's website after the conference.

### About Dicerna Pharmaceuticals, Inc.

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit [www.dicerna.com](http://www.dicerna.com).

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20150619005611/en/>

### Investor Contact:

Westwicke Partners  
Peter Vozzo, 443-213-0505  
[peter.vozzo@westwicke.com](mailto:peter.vozzo@westwicke.com)

or

### Media Contact:

SmithSolve  
Alex Van Rees, 973-442-1555 ext. 111  
[alex.vanrees@smithsolve.com](mailto:alex.vanrees@smithsolve.com)

Source: Dicerna Pharmaceuticals, Inc.

News Provided by Acquire Media